231 related articles for article (PubMed ID: 17195223)
1. Fracture risk with intermittent high-dose oral glucocorticoid therapy.
De Vries F; Bracke M; Leufkens HG; Lammers JW; Cooper C; Van Staa TP
Arthritis Rheum; 2007 Jan; 56(1):208-14. PubMed ID: 17195223
[TBL] [Abstract][Full Text] [Related]
2. Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study.
Amiche MA; Abtahi S; Driessen JHM; Vestergaard P; de Vries F; Cadarette SM; Burden AM
Arch Osteoporos; 2018 Mar; 13(1):30. PubMed ID: 29552730
[TBL] [Abstract][Full Text] [Related]
3. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy.
Van Staa TP; Laan RF; Barton IP; Cohen S; Reid DM; Cooper C
Arthritis Rheum; 2003 Nov; 48(11):3224-9. PubMed ID: 14613287
[TBL] [Abstract][Full Text] [Related]
4. Effects of Systemic Glucocorticoid Use on Fracture Risk: A Population-Based Study.
Koh JW; Kim J; Cho H; Ha YC; Kim TY; Lee YK; Kim HY; Jang S
Endocrinol Metab (Seoul); 2020 Sep; 35(3):562-570. PubMed ID: 32981298
[TBL] [Abstract][Full Text] [Related]
5. Low-dose oral glucocorticoid therapy and risk of osteoporotic fractures in patients with rheumatoid arthritis: a cohort study using the Clinical Practice Research Datalink.
Abtahi S; Driessen JHM; Burden AM; Souverein PC; van den Bergh JP; van Staa TP; Boonen A; de Vries F
Rheumatology (Oxford); 2022 Apr; 61(4):1448-1458. PubMed ID: 34255815
[TBL] [Abstract][Full Text] [Related]
6. Average daily glucocorticoid dose, number of prescription days, and cumulative dose in the initial 90 days of glucocorticoid therapy are associated with subsequent hip and clinical vertebral fracture risk: a retrospective cohort study using a nationwide health insurance claims database in Japan.
Iki M; Fujimori K; Nakatoh S; Tamaki J; Ishii S; Okimoto N; Imano H; Ogawa S
Osteoporos Int; 2024 May; 35(5):805-818. PubMed ID: 38267664
[TBL] [Abstract][Full Text] [Related]
7. Risk of vertebral and non-vertebral fractures in patients with sarcoidosis: a population-based cohort.
Bours S; de Vries F; van den Bergh JPW; Lalmohamed A; van Staa TP; Leufkens HGM; Geusens PPP; Drent M; Harvey NC
Osteoporos Int; 2016 Apr; 27(4):1603-1610. PubMed ID: 26630976
[TBL] [Abstract][Full Text] [Related]
8. Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study.
Lin SM; Yang SH; Liang CC; Huang HK
Osteoporos Int; 2018 Jan; 29(1):153-162. PubMed ID: 29032384
[TBL] [Abstract][Full Text] [Related]
9. Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials.
Amiche MA; Albaum JM; Tadrous M; Pechlivanoglou P; Lévesque LE; Adachi JD; Cadarette SM
Osteoporos Int; 2016 May; 27(5):1709-18. PubMed ID: 26694595
[TBL] [Abstract][Full Text] [Related]
10. A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids.
van Staa TP; Geusens P; Pols HA; de Laet C; Leufkens HG; Cooper C
QJM; 2005 Mar; 98(3):191-8. PubMed ID: 15728400
[TBL] [Abstract][Full Text] [Related]
11. Incidence of subsequent fractures in the UK between 1990 and 2012 among individuals 50 years or older.
van der Velde RY; Wyers CE; Geusens PPMM; van den Bergh JPW; de Vries F; Cooper C; van de Staa TP; Harvey NC
Osteoporos Int; 2018 Nov; 29(11):2469-2475. PubMed ID: 30030587
[TBL] [Abstract][Full Text] [Related]
12. Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study.
Abtahi S; Driessen JHM; Burden AM; Souverein PC; van den Bergh JP; van Staa TP; Boonen A; de Vries F
Ann Rheum Dis; 2021 Apr; 80(4):423-431. PubMed ID: 33310727
[TBL] [Abstract][Full Text] [Related]
13. Association between hand-grip strength and site-specific risks of major osteoporotic fracture: Results from the Japanese Population-based Osteoporosis Cohort Study.
Kamiya K; Kajita E; Tachiki T; Ikehara S; Kouda K; Sato Y; Tamaki J; Kagamimori S; Iki M
Maturitas; 2019 Dec; 130():13-20. PubMed ID: 31706431
[TBL] [Abstract][Full Text] [Related]
14. Oral glucocorticoid use is associated with an increased risk of fracture.
Steinbuch M; Youket TE; Cohen S
Osteoporos Int; 2004 Apr; 15(4):323-8. PubMed ID: 14762652
[TBL] [Abstract][Full Text] [Related]
15. Glucocorticoids Are Associated with an Increased Risk for Vertebral Fracture in Patients with Rheumatoid Arthritis.
Kim D; Cho SK; Park B; Jang EJ; Bae SC; Sung YK
J Rheumatol; 2018 May; 45(5):612-620. PubMed ID: 29545455
[TBL] [Abstract][Full Text] [Related]
16. Use of high-dose intermittent systemic glucocorticoids and the risk of fracture in patients with chronic obstructive pulmonary disease.
Oshagbemi OA; Burden AM; Shudofsky KN; Driessen JHM; Vestergaard P; Krings A; Franssen FME; van den Bergh J; de Vries F
Bone; 2018 May; 110():238-243. PubMed ID: 29462672
[TBL] [Abstract][Full Text] [Related]
17. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
Chesnut CH; Skag A; Christiansen C; Recker R; Stakkestad JA; Hoiseth A; Felsenberg D; Huss H; Gilbride J; Schimmer RC; Delmas PD;
J Bone Miner Res; 2004 Aug; 19(8):1241-9. PubMed ID: 15231010
[TBL] [Abstract][Full Text] [Related]
18. Fracture rate in patients with myasthenia gravis: the general practice research database.
Pouwels S; de Boer A; Javaid MK; Hilton-Jones D; Verschuuren J; Cooper C; Leufkens HG; de Vries F
Osteoporos Int; 2013 Feb; 24(2):467-76. PubMed ID: 22531999
[TBL] [Abstract][Full Text] [Related]
19. Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case-control study.
de Vries F; Pouwels S; Lammers JW; Leufkens HG; Bracke M; Cooper C; van Staa TP
J Intern Med; 2007 Feb; 261(2):170-7. PubMed ID: 17241182
[TBL] [Abstract][Full Text] [Related]
20. Statin Use Is Associated With Decreased Osteoporosis and Fracture Risks in Stroke Patients.
Lin SM; Wang JH; Liang CC; Huang HK
J Clin Endocrinol Metab; 2018 Sep; 103(9):3439-3448. PubMed ID: 29982482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
